Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Several companies, including Palantir and Eli Lilly, have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters.
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 7.7%. This drop is a noticeable divergence from the S&P 500’s 5.5% return.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
LLY has given back meaningful ground over recent horizons: the stock is down approximately $103.94 (≈-13.6%) month-to-date and about $119.68 (≈-15.4%) year-to-date.
Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market.
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed the year-on-year growth to ongoing strength from key products such as Mounjaro and Zepbound, with robust demand in both diabetes and obesity markets. CEO David A. Ricks highlighted the positive clinical data from the ATTAIN-1 orforglipron trial and strong uptake of new products, but acknowledged headwinds tied to U.S. drug pricing reforms, competitive pressures, and changes in pharmacy benefit manager coverage. Ricks also pointed to continued investment in research and development and manufacturing expansion as central to supporting future growth.
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital.
The select few that can do all three for many years are often the ones that make you life-changing money.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff.
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly.
Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading to millions in improper Medicaid claims.
Texas Attorney General Ken Paxton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs.
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases.
